 Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 | | 1997 | 5 | 1 | 6 | | 1998 | 4 | 0 | 4 | | 1999 | 5 | 0 | 5 | | 2000 | 4 | 2 | 6 | | 2001 | 5 | 1 | 6 | | 2002 | 5 | 2 | 7 | | 2003 | 5 | 2 | 7 | | 2004 | 4 | 1 | 5 | | 2005 | 13 | 1 | 14 | | 2006 | 12 | 1 | 13 | | 2007 | 6 | 1 | 7 | | 2008 | 13 | 2 | 15 | | 2009 | 15 | 1 | 16 | | 2010 | 5 | 2 | 7 | | 2011 | 14 | 2 | 16 | | 2012 | 15 | 2 | 17 | | 2013 | 21 | 4 | 25 | | 2014 | 23 | 3 | 26 | | 2015 | 14 | 5 | 19 | | 2016 | 28 | 4 | 32 | | 2017 | 36 | 0 | 36 | | 2018 | 28 | 2 | 30 | | 2019 | 20 | 4 | 24 | | 2020 | 28 | 2 | 30 | | 2021 | 25 | 1 | 26 | | 2022 | 19 | 0 | 19 | | 2023 | 22 | 1 | 23 | | 2024 | 21 | 3 | 24 | | 2025 | 20 | 0 | 20 | | 2026 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Bermack C, Singh S, Pei G, Patel SP, Wang L, Yee C. First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study. J Immunother Cancer. 2026 Apr 30; 14(4).
-
Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, Kött J, Zell T, Amaral T, Ascierto PA, Corrie P, Dummer R, Eggermont A, Guo J, Hassel JC, Jalving M, Johnson DB, Kandolf L, Kirkwood JM, Lebbé C, Lee R, Long GV, Lorigan P, Malvehy J, Mangana J, Mohr P, Patel SP, Rizos H, Robert C, Schadendorf D, Sondak VK, Svane IM, Wainstein A, Zager JS, Pantel K, Hauschild A, Gebhardt C. Translating ctDNA into cutaneous melanoma care: An international expert survey. Eur J Cancer. 2026 May 15; 239:116676.
-
Hwang JC, Huhmann LB, Cho K, Goryachev SD, Starink N, Weinstock MA, Asgari MM, Zheng C, Lu C, Feldman TC, Do NV, Gaziano JM, Semenov YR, Hurlbert MS, Fillmore NR, Hartman RI. Identification of Risk Factors for Acral Melanoma in US Veterans. JAMA Dermatol. 2026 03 01; 162(3):279-291.
-
Baird MA, Jewett CE, Malide DA, Kratz L, Cartagena-Rivera AX, Fischer RS, Waterman CM. Lamin B receptor upregulation in metastatic melanoma causes nuclear envelope fragility in confined migration during cancer invasion. Proc Natl Acad Sci U S A. 2026 Feb 24; 123(8):e2513031123.
-
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Feb; 7(2):272-282.
-
Yamauchi T, Luo Y, Menon DR, Couts K, Khan S, Goel A, Dinarello CA, Zhai Z, Fujita M. Human Alpha-1 Antitrypsin Suppresses Melanoma Growth by Promoting Tumor Differentiation and CD8+ T-Cell-Mediated Immunity. Biomolecules. 2026 01 12; 16(1).
-
Mattei J, Ruitao L, Davies MA, Wong MK, Diab A, Haydu LE, Patel SP, Amaria RN, McQuade JL, Tawbi H, Burton EM, Glitza IC. Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature. Melanoma Res. 2026 Feb 01; 36(1):31-42.
-
Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, Payne M, Hussain I, Kuzel T, O'Day S, Sheri A, Friedlander PA, Kumar S, Bergersen VS, Foss Ø, Ellingsen EB, Bjørheim J, Bechter OE. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. Eur J Cancer. 2026 Jan 17; 233:116162.
-
Geng D, Chen J, Sanchez A, Davalos SA, Wilcox P, Gonzales-Rivera D, Couts K, Tobin R, Robinson W, Nielsen AJ, Guo J, McCarter M, Crump L, Tsujimoto K, Wilky BA, Davila E. Melanoma leverages innate immune IRAK-M signaling to limit metastasis through PTPN22-Induced signaling repression. Cancer Lett. 2026 Feb 28; 639:218172.
-
Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, Sukrithan V, Ratan A, McCarter M, Salhia B, Colman H, Naqash AR, Puzanov I, Arnold S, Marin-Acevedo JA, Ganesan S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nat Commun. 2025 Nov 13; 16(1):9968.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|